{"id":"https://openalex.org/W7223083393","doi":"https://doi.org/10.3389/fonc.2026.1933232","title":"Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making","display_name":"Optimal timing of adjuvant immunotherapy after radical cystectomy in muscle-invasive bladder cancer: from calendar-based to MRD-guided decision making","publication_year":2026,"publication_date":"2026-10-21","ids":{"openalex":"https://openalex.org/W7223083393","doi":"https://doi.org/10.3389/fonc.2026.1933232","pmid":"https://pubmed.ncbi.nlm.nih.gov/42985454","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13732464"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2026.1933232","doi":"https://doi.org/10.3389/fonc.2026.1933232","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1933232","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933232/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933232/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033365467","display_name":"Nabih Naim","orcid":"https://orcid.org/0000-0003-4113-9271","observed_orcids":["https://orcid.org/0000-0003-4113-9271"]},"institutions":[{"id":"https://openalex.org/I184679254","display_name":"Saint Joseph University","ror":"https://ror.org/044fxjq88","country_code":"LB","type":"education","lineage":["https://openalex.org/I184679254"]}],"countries":["LB"],"is_corresponding":true,"raw_author_name":"Nabih Naim","raw_affiliation_strings":["Hematology Oncology Department, Saint Joseph University of Beirut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Oncology Department, Saint Joseph University of Beirut","institution_ids":["https://openalex.org/I184679254"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152249806","display_name":"Ahmad Saad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184679254","display_name":"Saint Joseph University","ror":"https://ror.org/044fxjq88","country_code":"LB","type":"education","lineage":["https://openalex.org/I184679254"]}],"countries":["LB"],"is_corresponding":false,"raw_author_name":"Ahmad Saad","raw_affiliation_strings":["Hematology Oncology Department, Saint Joseph University of Beirut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Oncology Department, Saint Joseph University of Beirut","institution_ids":["https://openalex.org/I184679254"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5159208567","display_name":"Nesrine Mohamad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I184679254","display_name":"Saint Joseph University","ror":"https://ror.org/044fxjq88","country_code":"LB","type":"education","lineage":["https://openalex.org/I184679254"]}],"countries":["LB"],"is_corresponding":false,"raw_author_name":"Nesrine Mohamad","raw_affiliation_strings":["Hematology Oncology Department, Saint Joseph University of Beirut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Oncology Department, Saint Joseph University of Beirut","institution_ids":["https://openalex.org/I184679254"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061525036","display_name":"Joseph Gergi Kattan","orcid":"https://orcid.org/0000-0003-4576-6248","observed_orcids":["https://orcid.org/0000-0003-4576-6248"]},"institutions":[{"id":"https://openalex.org/I184679254","display_name":"Saint Joseph University","ror":"https://ror.org/044fxjq88","country_code":"LB","type":"education","lineage":["https://openalex.org/I184679254"]}],"countries":["LB"],"is_corresponding":false,"raw_author_name":"Joseph Kattan","raw_affiliation_strings":["Hematology Oncology Department, Saint Joseph University of Beirut"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology Oncology Department, Saint Joseph University of Beirut","institution_ids":["https://openalex.org/I184679254"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5033365467"],"corresponding_institution_ids":["https://openalex.org/I184679254"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.65351394,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"16","issue":null,"first_page":"1933232","last_page":"1933232"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12695","display_name":"Urinary and Genital Oncology Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/muscle-invasive-bladder-cancer","display_name":"muscle-invasive bladder cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/adjuvant-immunotherapy","display_name":"adjuvant immunotherapy","score":0.984000027179718},{"id":"https://openalex.org/keywords/radical-cystectomy","display_name":"radical cystectomy","score":0.8529999852180481},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.8389999866485596},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/durvalumab","display_name":"durvalumab","score":0.9819999933242798},{"id":"https://openalex.org/keywords/measurable-residual-disease","display_name":"minimal residual disease","score":0.8730000257492065},{"id":"https://openalex.org/keywords/circulating-tumor-dna","display_name":"circulating tumor DNA","score":0.9990000128746033},{"id":"https://openalex.org/keywords/postoperative-recovery","display_name":"postoperative recovery","score":0.5289999842643738}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8831999897956848},{"id":"https://openalex.org/C2775910329","wikidata":"https://www.wikidata.org/wiki/Q245995","display_name":"Cystectomy","level":4,"score":0.7714999914169312},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.7096999883651733},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.6571999788284302},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.6312000155448914},{"id":"https://openalex.org/C2777742743","wikidata":"https://www.wikidata.org/wiki/Q19904005","display_name":"Durvalumab","level":5,"score":0.5939000248908997},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5878000259399414},{"id":"https://openalex.org/C2780352672","wikidata":"https://www.wikidata.org/wiki/Q504775","display_name":"Bladder cancer","level":3,"score":0.566100001335144},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5527999997138977},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5333999991416931},{"id":"https://openalex.org/C31174226","wikidata":"https://www.wikidata.org/wiki/Q64855140","display_name":"Perioperative","level":2,"score":0.47429999709129333},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.45249998569488525},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4481000006198883},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.424699991941452},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.41029998660087585},{"id":"https://openalex.org/C148482608","wikidata":"https://www.wikidata.org/wiki/Q17007018","display_name":"Clinical study design","level":3,"score":0.36809998750686646},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.367900013923645},{"id":"https://openalex.org/C2778363899","wikidata":"https://www.wikidata.org/wiki/Q23900955","display_name":"Window of opportunity","level":2,"score":0.3508000075817108},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3386000096797943},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.31869998574256897},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.303600013256073},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.28540000319480896},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.2831000089645386},{"id":"https://openalex.org/C2777381376","wikidata":"https://www.wikidata.org/wiki/Q21083261","display_name":"Avelumab","level":5,"score":0.27900001406669617},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.2768000066280365},{"id":"https://openalex.org/C128544194","wikidata":"https://www.wikidata.org/wiki/Q474859","display_name":"Translational research","level":2,"score":0.2694999873638153},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.26910001039505005},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.26109999418258667},{"id":"https://openalex.org/C3018227240","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant chemotherapy","level":4,"score":0.2558000087738037}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3389/fonc.2026.1933232","doi":"https://doi.org/10.3389/fonc.2026.1933232","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1933232","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933232/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmid:42985454","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42985454","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in oncology","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13732464","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13732464/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Oncol","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:89e5e3f5be9a43e88581068d219e4b06","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/89e5e3f5be9a43e88581068d219e4b06","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 16 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2026.1933232","doi":"https://doi.org/10.3389/fonc.2026.1933232","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2026.1933232","pdf_url":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1933232/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7223083393.pdf","grobid_xml":"https://content.openalex.org/works/W7223083393.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1975918912","https://openalex.org/W2017819617","https://openalex.org/W2062783581","https://openalex.org/W2074604431","https://openalex.org/W2086858064","https://openalex.org/W2102525230","https://openalex.org/W2605630275","https://openalex.org/W2727714681","https://openalex.org/W2790417589","https://openalex.org/W2949491365","https://openalex.org/W2975736787","https://openalex.org/W2988581606","https://openalex.org/W2994890349","https://openalex.org/W3012544261","https://openalex.org/W3041298459","https://openalex.org/W3138703636","https://openalex.org/W3163995648","https://openalex.org/W3168935284","https://openalex.org/W4242669880","https://openalex.org/W4281738617","https://openalex.org/W4315754639","https://openalex.org/W4392847680","https://openalex.org/W4402548582","https://openalex.org/W4402552345","https://openalex.org/W4403320624","https://openalex.org/W4411158264","https://openalex.org/W4415281041","https://openalex.org/W4415351494","https://openalex.org/W4416391871","https://openalex.org/W7125951174","https://openalex.org/W7130433278","https://openalex.org/W7133216443","https://openalex.org/W7156127380"],"related_works":["https://openalex.org/W7162648749","https://openalex.org/W7166666608","https://openalex.org/W7124268784","https://openalex.org/W4412984100","https://openalex.org/W4402126266","https://openalex.org/W4409822226","https://openalex.org/W3022249210","https://openalex.org/W4394018296","https://openalex.org/W7167944658","https://openalex.org/W4286447748"],"abstract_inverted_index":{"The":[0],"approval":[1],"of":[2,39,53,71],"adjuvant":[3,111],"nivolumab":[4],"and":[5,10,62,82,114,121,153],"pembrolizumab":[6],"following":[7],"radical":[8],"cystectomy":[9],"more":[11],"recently":[12],"perioperative":[13],"durvalumab-based":[14],"strategies":[15],"represents":[16],"a":[17,27,159],"significant":[18],"therapeutic":[19,137],"advance":[20],"in":[21,163],"muscle-invasive":[22],"bladder":[23],"cancer":[24],"(MIBC).":[25],"However,":[26],"question":[28],"that":[29,134,141,154],"has":[30],"received":[31],"limited":[32],"systematic":[33],"attention":[34],"concerns":[35],"the":[36,50,94,147],"optimal":[37],"timing":[38,98,130,156],"immunotherapy":[40],"initiation":[41,145],"after":[42],"surgery.":[43],"Current":[44],"recommendations":[45],"are":[46],"derived":[47],"entirely":[48],"from":[49],"eligibility":[51],"windows":[52],"pivotal":[54],"clinical":[55,102],"trials,":[56],"most":[57],"notably":[58],"CheckMate":[59],"274,":[60],"AMBASSADOR":[61],"NIAGARA,":[63],"which":[64],"mandated":[65],"randomization":[66],"within":[67,146],"approximately":[68],"120":[69],"days":[70],"cystectomy.":[72],"These":[73],"operational":[74],"thresholds":[75],"were":[76,83],"designed":[77],"to":[78],"ensure":[79],"postoperative":[80],"recovery":[81],"not":[84],"prospectively":[85],"validated":[86,136],"as":[87],"biologically":[88],"optimal.":[89],"This":[90],"review":[91],"critically":[92],"examines":[93],"biological":[95],"rationale":[96],"underpinning":[97],"considerations,":[99],"appraises":[100],"what":[101],"trials":[103],"have":[104],"actually":[105],"studied,":[106],"draws":[107],"cautious":[108],"parallels":[109],"with":[110],"chemotherapy":[112],"literature,":[113],"discusses":[115],"how":[116],"circulating":[117],"tumour":[118],"DNA":[119],"(ctDNA)":[120],"minimal":[122],"residual":[123],"disease":[124],"(MRD)":[125],"detection":[126],"may":[127],"eventually":[128],"redefine":[129],"decisions.":[131],"We":[132],"conclude":[133],"no":[135],"window":[138],"currently":[139],"exists,":[140],"available":[142],"evidence":[143],"supports":[144],"studied":[148],"timeframe":[149],"when":[150],"clinically":[151],"feasible,":[152],"prospective":[155],"analyzes":[157],"constitute":[158],"major":[160],"unmet":[161],"need":[162],"MIBC":[164],"research.":[165]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-22T00:00:00"}